(CercleFinance.com) – Roche announced on Wednesday that it had obtained CE marking for a companion diagnostic test to identify patients with metastatic breast cancer with low HER2 expression eligible for Enhertu, AstraZeneca’s new anticancer drug.
The ‘Ventana HER2 (4B5)’ test now includes an algorithm targeting HER2 levels to help doctors establish targeted therapy using Enhertu, an antibody-drug conjugate that specifically targets HER2.
According to Roche, nearly half of patients with metastatic breast cancer express low levels of HER2, a protein that promotes the growth of cancer cells.
Breast cancer recently overtook lung cancer as the most diagnosed cancer worldwide, with approximately 2.3 million new cases reported each year worldwide.
More than 685,000 annual deaths are attributed to this disease.
Copyright © 2024 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends using the buttons below.
